Challenges of therapeutic substitution of drugs for economic reasons: Focus on CVD prevention

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 871-878

  Johnston, Atholl ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cost control; Cost savings; Drug cost; Generic drugs; Substitution; Switching; Therapeutic equivalency

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG;

BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; DRUG CHOICE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC ASPECT; HUMAN; MEDICAL DECISION MAKING; NOTE; PATIENT COMPLIANCE; PATIENT DECISION MAKING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COST CONTROL; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; EUROPE; FEES, PHARMACEUTICAL; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PATIENT PREFERENCE; TETRAZOLES; THERAPEUTIC EQUIVALENCY; UNITED STATES; VALINE;

EID: 77949512690     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903578462     Document Type: Note

References (52)

1. CPMP: Note for Guidance on the Investigation of Bioavailability and Bioequivalence. July 2001. Available at: www.emea.europa.eu/pdfs/ human/qwp/140198enfin.pdf
2. FDA. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. March 2003. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm070124.pdf [Last accessed 13 October 2009]
3. Eon Labs. Study report number ANA-97-132 submitted by Eon Labs Manufacturing Inc., Laurelton, NY (USA) to the Illinois (USA) Department of Health British National Formulary No.55. London: BMJ Group and RPS Publishing, 2008
4. Health and Social Care Board. Items unsuitable for generic prescribing 2009: Available at: www.dhsspsni.gov.uk/generic-exception-list---regional-aug- 09--final-.pdf [Last accessed 13 October 2009]
5. Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy. Case evidence of breakthrough seizures. Neurology 2008;71:525-530
6. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease. A systematic review and meta-analysis. JAMA 2008;300:2514-2526
7. Raw AS, Furness MS, Gill DS, et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev 2004;56:397-414
8. Tayrouz Y, Ding R, Burhenne J, et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-405
9. Wandel C, Kim RB, Stein CM. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharm Ther 2003;73:394-396
10. Kovarik JM, Noe A, Wang Y, et al. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006;62:361-366
11. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004;34:341-348
12. FDA. Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg. April 2008. Available at: http://www.fda.gov/ AboutFDA/CentersOffices/CDER/ucm153270.htm. [Last accessed 13 October 2009]
13. Hellström J, Rudholm N. Side effects of generic competition? Eur J Health Econom 2004;5:203-208
14. Reiffel JA, Kowey PR. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol 2000;85:1151-1153
15. Epilepsy Action. Anti-epileptic medication packaging survey. Available at: http://www.epilepsy.org.uk/campaigns/survey/aedpackaging. [Last accessed 13 October 2009]
16. Burkhardt RT, Leppik IE, Blesi K, et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004; 63:1494-1496
17. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-808
18. MHRA: Drug Safety Update 2009;2(6). Available at: http://www.mhra.gov.uk/ Publications/Safetyguidance/DrugSafetyUpdate/CON035989 [Last accessed 13 October 2009]
19. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007;9:58
20. ACOG. ACOG Issues New Opinion on Brand vs. Generic Oral Contraceptives. August 2007. Available at: www.acog.org/from-home/publications/press- releases/nr08-01-07-1.cfm. [Last accessed 13 October 2009]
21. Gerbino PP, Joseph AS. Multisource drugs: implications and concerns in the geriatric population. Hosp Pharm 1993;28:96-98,101-102
22. Treur M, Heeg B, Mö ller HJ, et al. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res 2009;9:32
23. Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23: 2101-2107
24. Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-656
25. Ringe JD, Mö ller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postme-nopausal osteoporosis:1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;May 9 [Epub ahead of print]
26. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243-249
27. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530
28. Switching statins. Bandolier 157 2007;14(3):1-8
29. Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-285
30. Wiviott SD, Braunwald E, McCabe CH, et al for the TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-2015
31. Pedersen TR, Faergeman P, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled Trial. JAMA 2005;294:2437-2445
32. Harris International. Consumers' views on therapeutic substitution. September 2008. Available at: http://www.nclnet.org/health/therapeutic- substitution.pdf. [Last accessed 13 October 2009]
33. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 2002;346:822-829
34. Dahlöf B, Sever PS, Poulter NR, et al. for the ASCOT investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
35. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-681
36. Marentette MA, Gerth WC, Billings, DK, et al. Antihypertensive Persistence and drug class. Can J Cardiol 2002;18:649-656
37. Pylypchuk GB. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-1066
38. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 2005;28:601-631
39. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
40. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-46
41. Schroeder SA, Cantor JC. On squeezing balloons. Cost control fails again. N Engl J Med 1991;325:1099-1100
42. National Institute of Health. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. NIH, 2003
43. Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006;28: 284-289
44. Dowell JS, Snadden D, Dunbar JA. Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ 1995;310:505-508
45. Dealing with the downturn: the greatest ever leadership challenge for the NHS? Available at: http://www.nhsconfed.org/Publications/Documents/ Dealing-with-the-downturn.pdf. [Last accessed 13 October 2009]
46. BMA response. A review of the consequences of additional private drugs for NHS care. Led by Professor Mike Richards on behalf of the Secretary of State for Health. Available at: http://www.bma.org.uk/images/RichardsReview- tcm41-178745.pdf. [Last accessed 13 October 2009]
47. Council of Europe Health Policy. Available at: http://www.coe.int/t/dg3/ health/ recommendations-en.asp#policy. [Last accessed 13 October 2009]
48. WHO Rational Use of Medicines: Activities. Available at: http://www.who.int/ medicines/areas/rational-use/rud-activities/en/index.html. [Last accessed 13 October 2009]
49. The European Directorate for the Quality of Medicines and healthcare (EDQM). Available at: http://www.edqm.eu/site/Pharmaceuticals-Pharmaceutical- care-1271.html. [Last accessed 13 October 2009]
50. Figueras J, McKee M, Lessof S, et al. Health systems, health and wealth: Assessing the case for investing in health systems. World Health Organization 2008 and World Health Organization, on behalf of the European Observatory on Health Systems and Policies 2008. Available at: http://www.euro.who.int/ document/hsm/3-hsc08-eBD3.pdf. [Last accessed 13 October 2009]
51. The European Federation of Pharmaceutical Industries and Associations (EFPIA): Position Paper. Use of HTAs to evaluate medicines (July 2005). Available at: http://212.3.246.100/Objects/2/Files/HTAprinciplesEFPIA positionpaperFinal.pdf. [Last accessed 13 October 2009]
52. The Pharmaceutical Price Regulation Scheme (PPRS). Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH-091825. [Last accessed 13 October 2009]